COMP <GO>
CCM vs ABBV // EV/EBITDA & P/E VALUATION
Concord Medical Services Holdings Limited (Each represents thirty (30) ) (Class A) (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: CCM 1
— ABBV 9
■ METRIC PARITY
CCM — Concord Medical Services Holdings Limited (Each represents thirty (30) ) (Class A)
ROARABLE E • RQD 22/100
LAST: $3.66 (-4.93%) • MKT CAP: $15.9M
valuation
—
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CCM VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CCM | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 5.70% | 70.20% | -64.50 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 29.00% | -64.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 3.47% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -57.60% | 24.60% | -82.20 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -20.40% | 6.90% | -27.30 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 26.60% | 8.60% | +18.00 | CCM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.33 | -5.13 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 7/9 | -5.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.6 | 65.1 | -17.52 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $15.9M | $513.86B | -$513.84B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CCM REV | ABBV REV | CCM GROSS % | ABBV GROSS % | CCM FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $65.0M | $61.16B | 5.7% | 70.2% | -$36.9M | $17.82B |
| FY 2024 | $51.3M | $56.33B | -21.1% | 70.0% | -$75.1M | $17.83B |
| FY 2023 | $73.3M | $54.32B | — | — | -$38.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CCM // BETA —
ABBV // BETA 1.15